生命银行
睾酮(贴片)
内科学
内分泌学
医学
生物
生理学
老年学
遗传学
人口学
社会学
作者
Lynn Ogoniak,Sarah Sandmann,Julian Varghese,Michael J. Ziller,Nina Neuhaus,Alexander S. Busch
出处
期刊:PubMed
日期:2025-07-17
标识
DOI:10.1093/ejendo/lvaf143
摘要
Age-related decline in circulating testosterone levels in men varies significantly and is often linked to comorbidities such as type 2 diabetes, and cardiovascular disease (CVD). While the genetic basis of testosterone levels is well-studied, the role of genetics in age-related testosterone decline remains unclear. This study aims to investigate the genetic contribution to age-related testosterone decline in men and its association with comorbidities. A longitudinal, population-based study in 6,354 men including consecutive testosterone (T), bioavailable testosterone (BAT), and sex hormone-binding globulin (SHBG) measurements. We assessed the association of longitudinal serum biomarker changes with changes in disease prevalences and a polygenic score (PGS) for BAT developed in 183,909 UK Biobank participants. In the follow-up cohort (mean age: 58.2 years; mean follow-up: 4.3 years), baseline levels of BAT, T, and SHBG were each negatively associated with their respective relative changes at follow-up (all p<0.001). A PGS for BAT, strongly associated with baseline levels (p=2.2x10-16, R²=0.16), was not associated with BAT decline over time. Genome-wide analysis of BAT change identified no significant genetic loci. Instead, the BAT decline was associated with prevalence of several comorbidities including cancers and CVD (p=0.007 and 0.012, respectively). Non-genetic factors are strongly associated with age-related BAT decline, whereas genetic predisposition may have a limited role. However, this does not rule out a potential genetic contribution. Our findings offer insight into the relationship between comorbidities and hormonal changes, supporting further research into their roles in testosterone decline and related health risks in aging men.
科研通智能强力驱动
Strongly Powered by AbleSci AI